One Platform. Two Critical Gaps:
General Anesthesia Reversal and OIRD Rescue
The Most Perilous Drug Crisis Ever and We Have One Pharmaceutical Tool...
Until Now.
Targeting $95B in Overdose Treatment Costs Annually
OYE's drug product can make treatment of opioid overdose (i.e. naloxone) safer, more effective, and more efficient, helping to shorten ER length of stay, reduce backlogs, and improve outcomes.
Data That
Tells a Story
Over 100,000 Deaths per Year
Fentanyl alone has become the leading cause of death among Americans 18-44.
Naloxone Alone Is Not Enough
1. Duration of Action is Too Short, 20-minutes
2. Over 25% of Patients Relapse into Opioid Induced Respiratory Depression (OIRD)
OYE's Drug Product Will Save Lives in Multiple Clinical Settings
1. Emergency Departments (ER)
2. Ambulance and EMS vehicles
3. Med-Surg units in every hospital
4. PACU/Surgery Centers (ASC)
5. Military Medicine and VA
“Society must continue developing new tools and approaches for preventing overdose deaths”
— Nora Volkow, NIH NIDA Director 2024 NEJM
OYE Therapeutics
Revolutionizing Treatment of Opioid Overdose
OYE Therapeutics is a clinical stage pharmaceutical development company. We are focused on bringing innovation to market that offers a positive return on investment in the form of improved safety, efficacy, equity, outcomes, and cost savings.